Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma

Gaetano Apice, Antonio Pizzolorusso, Massimo Di Maio, Giovanni Grignani, V. Gebbia, Angela Buonadonna, Anna Rosaria De Chiara, Flavio Fazioli, Gianpaolo De Palma, Danilo Galizia, C. Arcara, Nicola Mozzillo, Francesco Perrone

Research output: Contribution to journalArticle

Abstract

Background. In several prospective and retrospective studies, weekly paclitaxel showed promising activity in patients with angiosarcoma. Patients and Methods. Our study was originally designed as a prospective, phase II multicenter trial for patients younger than 75, with ECOG performance status 0-2, affected by locally advanced or metastatic angiosarcoma. Patients received paclitaxel 80 mg/m2 intravenously, at days 1, 8, and 15 every 4 weeks, until disease progression or unacceptable toxicity. Primary endpoint was objective response. Results. Eight patients were enrolled but, due to very slow accrual, the trial was prematurely stopped and further 10 patients were retrospectively included in the analysis. Out of 17 evaluable patients, 6 patients obtained an objective response (5 partial, 1 complete), with an objective response rate of 35% (95% confidence interval 17%-59%). Of note, five responses were obtained in pretreated patients. In the paper, details of overall survival, progression-free survival, and tolerability are reported. Conclusions. In this small series of patients with locally advanced or metastatic angiosarcoma, weekly paclitaxel was confirmed to be well tolerated and active even in pretreated patients.

Original languageEnglish
Article number6862090
JournalSarcoma
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Hemangiosarcoma
Paclitaxel
Therapeutics
Multicenter Studies
Disease-Free Survival
Disease Progression
Retrospective Studies
Prospective Studies
Confidence Intervals

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

@article{46df49fb73a44b128dd8834368d0ef57,
title = "Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma",
abstract = "Background. In several prospective and retrospective studies, weekly paclitaxel showed promising activity in patients with angiosarcoma. Patients and Methods. Our study was originally designed as a prospective, phase II multicenter trial for patients younger than 75, with ECOG performance status 0-2, affected by locally advanced or metastatic angiosarcoma. Patients received paclitaxel 80 mg/m2 intravenously, at days 1, 8, and 15 every 4 weeks, until disease progression or unacceptable toxicity. Primary endpoint was objective response. Results. Eight patients were enrolled but, due to very slow accrual, the trial was prematurely stopped and further 10 patients were retrospectively included in the analysis. Out of 17 evaluable patients, 6 patients obtained an objective response (5 partial, 1 complete), with an objective response rate of 35{\%} (95{\%} confidence interval 17{\%}-59{\%}). Of note, five responses were obtained in pretreated patients. In the paper, details of overall survival, progression-free survival, and tolerability are reported. Conclusions. In this small series of patients with locally advanced or metastatic angiosarcoma, weekly paclitaxel was confirmed to be well tolerated and active even in pretreated patients.",
author = "Gaetano Apice and Antonio Pizzolorusso and {Di Maio}, Massimo and Giovanni Grignani and V. Gebbia and Angela Buonadonna and {De Chiara}, {Anna Rosaria} and Flavio Fazioli and {De Palma}, Gianpaolo and Danilo Galizia and C. Arcara and Nicola Mozzillo and Francesco Perrone",
year = "2016",
doi = "10.1155/2016/6862090",
language = "English",
volume = "2016",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma

AU - Apice, Gaetano

AU - Pizzolorusso, Antonio

AU - Di Maio, Massimo

AU - Grignani, Giovanni

AU - Gebbia, V.

AU - Buonadonna, Angela

AU - De Chiara, Anna Rosaria

AU - Fazioli, Flavio

AU - De Palma, Gianpaolo

AU - Galizia, Danilo

AU - Arcara, C.

AU - Mozzillo, Nicola

AU - Perrone, Francesco

PY - 2016

Y1 - 2016

N2 - Background. In several prospective and retrospective studies, weekly paclitaxel showed promising activity in patients with angiosarcoma. Patients and Methods. Our study was originally designed as a prospective, phase II multicenter trial for patients younger than 75, with ECOG performance status 0-2, affected by locally advanced or metastatic angiosarcoma. Patients received paclitaxel 80 mg/m2 intravenously, at days 1, 8, and 15 every 4 weeks, until disease progression or unacceptable toxicity. Primary endpoint was objective response. Results. Eight patients were enrolled but, due to very slow accrual, the trial was prematurely stopped and further 10 patients were retrospectively included in the analysis. Out of 17 evaluable patients, 6 patients obtained an objective response (5 partial, 1 complete), with an objective response rate of 35% (95% confidence interval 17%-59%). Of note, five responses were obtained in pretreated patients. In the paper, details of overall survival, progression-free survival, and tolerability are reported. Conclusions. In this small series of patients with locally advanced or metastatic angiosarcoma, weekly paclitaxel was confirmed to be well tolerated and active even in pretreated patients.

AB - Background. In several prospective and retrospective studies, weekly paclitaxel showed promising activity in patients with angiosarcoma. Patients and Methods. Our study was originally designed as a prospective, phase II multicenter trial for patients younger than 75, with ECOG performance status 0-2, affected by locally advanced or metastatic angiosarcoma. Patients received paclitaxel 80 mg/m2 intravenously, at days 1, 8, and 15 every 4 weeks, until disease progression or unacceptable toxicity. Primary endpoint was objective response. Results. Eight patients were enrolled but, due to very slow accrual, the trial was prematurely stopped and further 10 patients were retrospectively included in the analysis. Out of 17 evaluable patients, 6 patients obtained an objective response (5 partial, 1 complete), with an objective response rate of 35% (95% confidence interval 17%-59%). Of note, five responses were obtained in pretreated patients. In the paper, details of overall survival, progression-free survival, and tolerability are reported. Conclusions. In this small series of patients with locally advanced or metastatic angiosarcoma, weekly paclitaxel was confirmed to be well tolerated and active even in pretreated patients.

UR - http://www.scopus.com/inward/record.url?scp=84960981921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960981921&partnerID=8YFLogxK

U2 - 10.1155/2016/6862090

DO - 10.1155/2016/6862090

M3 - Article

VL - 2016

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 6862090

ER -